1. Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort
- Author
-
Rachel Neff Greenley, Alisha Michelle Mavis, Diana G. Lerner, David S. Vitale, and Steven L. Werlin
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Inflammatory bowel disease ,Medical Records ,Maintenance Chemotherapy ,Medication Adherence ,Cohort Studies ,Wisconsin ,Crohn Disease ,Gastrointestinal Agents ,Acute care ,Internal medicine ,medicine ,Humans ,Child ,Infusions, Intravenous ,Retrospective Studies ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Gastroenterology ,Hospitals, Pediatric ,Symptom Flare Up ,medicine.disease ,Infliximab ,Hospitalization ,Disease factors ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Cohort ,Colitis, Ulcerative ,Female ,Emergency Service, Hospital ,business ,medicine.drug - Abstract
The aims of the study were to describe infliximab adherence in a pediatric inflammatory bowel disease cohort, to identify demographic and disease factors associated with adherence, and to examine differences in acute care use among adherent and nonadherent patients. Charts of patients who received infliximab at the Children's Hospital of Wisconsin (CHW) between October 2010 and October 2012 were retrospectively reviewed. A total of 151 patients met the inclusion criteria; 91.4% of the patients were adherent. Nonadherent patients had more emergency room visits and hospitalizations than adherent patients. The study is the first to show high adherence rates to infliximab in a pediatric cohort.
- Published
- 2015
- Full Text
- View/download PDF